Document Classification

Section Type: RESULTS

Text: Edifoligide had no effect on the primary end point of per patient vein graft failure (436 [45. 2 %] of 965 patients in the edifoligide group vs 442 [46. 3 %] of 955 patients in the placebo group ; odds ratio, 0. 96 [95 % confidence interval { CI }, 0. 80-1. 14] ; P =. 66), on any secondary angiographic end point, or on the incidence of major adverse cardiac events at 1 year (101 [6. 7 %] of 1508 patients in the edifoligide group vs 121 [8. 1 %] of 1506 patients in the placebo group ; hazard ratio, 0. 83 [95 % CI, 0. 64-1. 08] ; P =. 16).